Supplementary Figure 2 from <i>PIK3CA</i> Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma

PDF File - 95K, K-M curves according to mutation sites.</p

Supplementary Table 2 from <i>PIK3CA</i> Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma

PDF File - 28K, Number at risk in survival analyses.</p

Supplementary Table 1 from <i>PIK3CA</i> Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma

PDF File - 44K, PIK3CA mutations in ESCC.</p

Supplementary Figure 1 from <i>PIK3CA</i> Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma

PDF File - 358K, Immunohistochemistry for p-AKT and p53.</p

Supplementary Figure 3 from <i>PIK3CA</i> Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma

PDF File - 127K, K-M curves in cases without preoperative treatment (left panel) and in cases with preoperative treatment (right panel).</p

Analysis of survival in relation to change in skeletal muscle after chemotherapy in patients with unresectable colorectal cancer.

<p>Kaplan–Meier survival curves of progression-free survival (A) and overall survival (C) according to quartiles (Q1–Q4) based on change in skeletal muscle after chemotherapy in patients with unresectable colorectal cancer. (B) and (D) show differences in PFS and OS, respectively, between Q1 and Q2–4. Q1 represents the skeletal-muscle-loss group and Q2, Q3 and Q4 collectively represent the non-skeletal-muscle-loss group.</p

Flow chart representing the study selection process.

<p>Flow chart representing the study selection process.</p

Rate of skeletal muscle change after chemotherapy and clinical and tumour features in patients with unresectable colorectal cancer.

<p>Abbreviations: CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor.</p><p>Values given as mean ± standard deviation or number (%).</p><p>Rate of skeletal muscle change after chemotherapy and clinical and tumour features in patients with unresectable colorectal cancer.</p

Supplementary Figure 1 from LINE-1 Hypomethylation, DNA Copy Number Alterations, and <i>CDK6</i> Amplification in Esophageal Squamous Cell Carcinoma

PDF file - 195K, The result of CGH arrays in 6 cases.</p

Supplementary Table 1 from LINE-1 Hypomethylation, DNA Copy Number Alterations, and <i>CDK6</i> Amplification in Esophageal Squamous Cell Carcinoma

PDF file - 40K, Clinical and pathological characteristics of 6 cases selected for CGH array.</p